Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Consensus Rating of "Moderate Buy" from Analysts

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the twenty-one analysts that are covering the stock, Marketbeat reports. Nine analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $40.05.

A number of research firms have weighed in on APLS. Wells Fargo & Company raised their price target on Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an "equal weight" rating in a research note on Monday, June 2nd. Bank of America cut Apellis Pharmaceuticals from a "buy" rating to a "neutral" rating and cut their target price for the stock from $41.00 to $23.00 in a research report on Friday, May 9th. Needham & Company LLC cut their target price on Apellis Pharmaceuticals from $40.00 to $29.00 and set a "buy" rating on the stock in a research report on Wednesday, May 7th. The Goldman Sachs Group cut their target price on Apellis Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating on the stock in a research report on Monday, March 3rd. Finally, Robert W. Baird cut their target price on Apellis Pharmaceuticals from $55.00 to $47.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th.

Hedge Funds Weigh In On Apellis Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Avoro Capital Advisors LLC boosted its holdings in Apellis Pharmaceuticals by 10.0% in the 4th quarter. Avoro Capital Advisors LLC now owns 12,222,222 shares of the company's stock valued at $390,011,000 after purchasing an additional 1,111,111 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Apellis Pharmaceuticals by 0.8% in the 1st quarter. Vanguard Group Inc. now owns 10,130,356 shares of the company's stock valued at $221,551,000 after purchasing an additional 84,331 shares in the last quarter. AQR Capital Management LLC boosted its holdings in Apellis Pharmaceuticals by 119.6% in the 1st quarter. AQR Capital Management LLC now owns 4,077,419 shares of the company's stock valued at $89,173,000 after purchasing an additional 2,220,977 shares in the last quarter. Geode Capital Management LLC boosted its holdings in Apellis Pharmaceuticals by 1.6% in the 4th quarter. Geode Capital Management LLC now owns 1,838,952 shares of the company's stock valued at $58,699,000 after purchasing an additional 28,426 shares in the last quarter. Finally, Deutsche Bank AG boosted its holdings in Apellis Pharmaceuticals by 1.8% in the 4th quarter. Deutsche Bank AG now owns 1,778,377 shares of the company's stock valued at $56,748,000 after purchasing an additional 30,867 shares in the last quarter. Hedge funds and other institutional investors own 96.29% of the company's stock.

Apellis Pharmaceuticals Stock Down 2.2%

Apellis Pharmaceuticals stock opened at $18.83 on Friday. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $43.15. The company has a debt-to-equity ratio of 1.91, a current ratio of 4.36 and a quick ratio of 3.73. The stock has a market cap of $2.37 billion, a PE ratio of -9.28 and a beta of 0.68. The stock's fifty day moving average is $18.31 and its two-hundred day moving average is $25.26.

Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts' consensus estimates of ($0.36) by ($0.38). Apellis Pharmaceuticals had a negative net margin of 34.97% and a negative return on equity of 103.11%. The business had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. During the same quarter in the prior year, the business earned ($0.54) earnings per share. The firm's quarterly revenue was down 3.2% on a year-over-year basis. On average, sell-side analysts expect that Apellis Pharmaceuticals will post -1.7 EPS for the current fiscal year.

About Apellis Pharmaceuticals

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.